GB0512844D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0512844D0
GB0512844D0 GBGB0512844.2A GB0512844A GB0512844D0 GB 0512844 D0 GB0512844 D0 GB 0512844D0 GB 0512844 A GB0512844 A GB 0512844A GB 0512844 D0 GB0512844 D0 GB 0512844D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0512844.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0512844.2A priority Critical patent/GB0512844D0/en
Publication of GB0512844D0 publication Critical patent/GB0512844D0/en
Priority to BRPI0613394-0A priority patent/BRPI0613394A2/pt
Priority to CA002610742A priority patent/CA2610742A1/en
Priority to AU2006261122A priority patent/AU2006261122A1/en
Priority to US11/993,630 priority patent/US20100179127A1/en
Priority to JP2008517430A priority patent/JP2008546731A/ja
Priority to KR1020077029918A priority patent/KR20080017382A/ko
Priority to MX2007016395A priority patent/MX2007016395A/es
Priority to EP06762168A priority patent/EP1896428A1/en
Priority to CNA2006800207941A priority patent/CN101193868A/zh
Priority to PCT/EP2006/006083 priority patent/WO2006136442A1/en
Priority to RU2008101525/04A priority patent/RU2008101525A/ru
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0512844.2A 2005-06-23 2005-06-23 Organic compounds Ceased GB0512844D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB0512844.2A GB0512844D0 (en) 2005-06-23 2005-06-23 Organic compounds
RU2008101525/04A RU2008101525A (ru) 2005-06-23 2006-06-23 Производные пиримидина для лечения заболеваний нервной системы, опосредуемых гаммааминомасляной кислотой в (гамк в)
US11/993,630 US20100179127A1 (en) 2005-06-23 2006-06-23 Pyrimidine derivatives
CA002610742A CA2610742A1 (en) 2005-06-23 2006-06-23 Pyrimidine derivatives for the treatment op gaba b mediated nervous system disorders
AU2006261122A AU2006261122A1 (en) 2005-06-23 2006-06-23 Pyrimidine derivatives for the treatment of GABA B mediated nervous system disorders
BRPI0613394-0A BRPI0613394A2 (pt) 2005-06-23 2006-06-23 derivados de pirimidina
JP2008517430A JP2008546731A (ja) 2005-06-23 2006-06-23 Ｇａｂａｂ仲介神経系障害の処置のためのピリミジン誘導体
KR1020077029918A KR20080017382A (ko) 2005-06-23 2006-06-23 Ｇａｂａ ｂ 매개된 신경계 장애 치료용 피리미딘 유도체
MX2007016395A MX2007016395A (es) 2005-06-23 2006-06-23 Derivados de pirimidina para el tratamiento de trastornos del sistema nervioso mediados por gaba b.
EP06762168A EP1896428A1 (en) 2005-06-23 2006-06-23 Pyrimidine derivatives for the treatment op gaba b mediated nervous system disorders
CNA2006800207941A CN101193868A (zh) 2005-06-23 2006-06-23 治疗gaba b介导的神经系统障碍的嘧啶衍生物
PCT/EP2006/006083 WO2006136442A1 (en) 2005-06-23 2006-06-23 Pyrimidine derivatives for the treatment op gaba b mediated nervous system disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0512844.2A GB0512844D0 (en) 2005-06-23 2005-06-23 Organic compounds

Publications (1)

Publication Number Publication Date
GB0512844D0 true GB0512844D0 (en) 2005-08-03

Family

ID=34856051

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0512844.2A Ceased GB0512844D0 (en) 2005-06-23 2005-06-23 Organic compounds

Country Status (12)

Country Link
US (1) US20100179127A1 (enExample)
EP (1) EP1896428A1 (enExample)
JP (1) JP2008546731A (enExample)
KR (1) KR20080017382A (enExample)
CN (1) CN101193868A (enExample)
AU (1) AU2006261122A1 (enExample)
BR (1) BRPI0613394A2 (enExample)
CA (1) CA2610742A1 (enExample)
GB (1) GB0512844D0 (enExample)
MX (1) MX2007016395A (enExample)
RU (1) RU2008101525A (enExample)
WO (1) WO2006136442A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520975A (ja) 2008-05-19 2011-07-21 ユニヴァーシティ オブ テネシー リサーチ ファウンデーション，ザ ピリミジンの非古典的カンナビノイド化合物及び関連する使用方法
US8389534B2 (en) 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5619743B2 (ja) * 2008-08-20 2014-11-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8541434B2 (en) 2008-08-20 2013-09-24 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010045377A2 (en) * 2008-10-14 2010-04-22 University Of Tennessee Research Foundation, The Pyrimidine non-classical cannabinoid compounds and related methods of use
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CZ305457B6 (cs) * 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
LT2718270T (lt) 2011-06-10 2022-08-10 Merck Patent Gmbh Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
EP2773207B1 (en) * 2011-10-31 2018-03-07 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9637505B2 (en) 2013-03-15 2017-05-02 Dow Agrosciences Llc 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
KR102305436B1 (ko) 2013-03-15 2021-09-27 코르테바 애그리사이언스 엘엘씨 4-아미노-6-(헤테로시클릭)피콜리네이트 및 6-아미노-2-(헤테로시클릭)피리미딘-4-카르복실레이트 및 제초제로서의 그의 용도
WO2014151009A1 (en) * 2013-03-15 2014-09-25 Dow Agrosciences Llc 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic) pyrimidine-4-carboxylates and their use as herbicides
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
TWI689251B (zh) 2014-09-15 2020-04-01 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與合成生長素除草劑及/或生長素轉運抑制劑的協同性雜草控制
US10455836B2 (en) 2014-09-15 2019-10-29 Dow Agrosciences Llc Synergistic weed control from applications of pyridine carboxylic acid herbicides and photosystem II inhibitors
AR101858A1 (es) 2014-09-15 2017-01-18 Dow Agrosciences Llc Composiciones herbicidas protegidas que comprenden un herbicida de ácido piridincarboxílico
TWI685302B (zh) 2014-09-15 2020-02-21 美商陶氏農業科學公司 包含吡啶羧酸除草劑之安全的除草組成物
TWI689252B (zh) 2014-09-15 2020-04-01 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與乙醯乳酸合成酶（ａｌｓ）抑制劑的協同性雜草控制
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3377484B1 (en) * 2015-11-17 2023-09-06 Merck Patent GmbH Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022029666A1 (en) 2020-08-05 2022-02-10 Richter Gedeon Nyrt. PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH560197A5 (en) * 1971-05-17 1975-03-27 Ciba Geigy Ag 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
CH558137A (de) * 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
CH574206A5 (enExample) * 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2341925A1 (de) * 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
CH595061A5 (enExample) * 1974-05-10 1978-01-31 Ciba Geigy Ag
CH617833A5 (enExample) * 1975-07-07 1980-06-30 Ciba Geigy Ag
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
EA005927B1 (ru) * 2000-06-13 2005-08-25 Басф Акциенгезельшафт Фунгицидные 5-фенил-замещенные 2-(цианоамино)пиримидины
SE0004099D0 (sv) * 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CN1976905A (zh) * 2004-03-30 2007-06-06 大正制药株式会社 嘧啶衍生物以及与其应用有关的治疗方法

Also Published As

Publication number Publication date
US20100179127A1 (en) 2010-07-15
CN101193868A (zh) 2008-06-04
JP2008546731A (ja) 2008-12-25
KR20080017382A (ko) 2008-02-26
WO2006136442A1 (en) 2006-12-28
BRPI0613394A2 (pt) 2011-01-11
RU2008101525A (ru) 2009-07-27
EP1896428A1 (en) 2008-03-12
MX2007016395A (es) 2008-03-07
AU2006261122A1 (en) 2006-12-28
CA2610742A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
GB0510390D0 (en) Organic compounds
GB0512844D0 (en) Organic compounds
GB0507575D0 (en) Organic compounds
GB0500435D0 (en) Organic compounds
GB0507696D0 (en) Organic compounds
GB0500785D0 (en) Organic compounds
GB0505969D0 (en) Organic compounds
GB0502358D0 (en) Organic compounds
GB0505219D0 (en) Organic compounds
GB0503646D0 (en) Organic compounds
GB0507298D0 (en) Organic compounds
GB0504850D0 (en) Organic compounds
GB0504194D0 (en) Organic compounds
GB0526614D0 (en) Organic compounds
GB0504544D0 (en) Organic compounds
GB0501237D0 (en) Organic compounds
GB0508992D0 (en) Organic compounds
GB0511066D0 (en) Organic compounds
GB0500784D0 (en) Organic compounds
GB0511686D0 (en) Organic compounds
GB0500020D0 (en) Organic compounds
GB0511063D0 (en) Organic compounds
GB0505541D0 (en) Organic compounds
GB0500683D0 (en) Organic compounds
GB0511684D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)